My ePortfolio Register   

ASH 2016 /
Pacritinib versus best available therapy for low platelet Myelofibrosis

3rd - 6th Dec 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.16
Views: 697

Dr John Mascarenhas - Mount Sinai School of Medicine New York, USA

Dr Mascarenhas speaks with ecancertv at ASH 2016 about pacritinib, an oral kinase inhibitor against JAK2, FLT3, IRAK1, and CSF1R.

He describes the patient response to pacritinib, with a direct comparison to ruxolitinib (a JAK1/2 inhibitor) being of significant interest, and weighs measuring spleen volume reduction against other endpoints.

Pacritinib is currently on full clinical hold by the FDA following deaths and cardiac events in PERSIST-1, which Dr Mascarenhas considers against the toxicity profile in this trial.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence